A multi-target
RNA inhibitor, relating to the field of
nucleic acid drugs, and having specific structures as shown in the following general formulae Ia and Ib. X1 and X2 are orthogonal reactive groups, and the orthogonal reactive groups comprise, but are not limited to: one or more of amino groups, amido groups,
carboxylic acid groups, azides, alkynes,
propargyl groups, dibenzocyclooctyne (DBCO), phosphoesters,
maleimide groups, aminooxy groups, N-hydroxysuccinimide (NHS), PNP, TFP, PFP, bromo groups, aldehydes,
carbonate groups,
tosyl groups, tetrazines, trans-
cyclooctene (TCO), hydrazides, hydroxyl groups, disulfides and o-pyridyl disulfide groups, bicyclo[6.1.0]nonyne (BCN), and free or protected
thiol groups. Za, Zb, Zc and Zd are delivery ligands or H, k is an integer from 0 to 4; and L1, L2, L3 and L4 are connecting chains or bonds. The present invention can achieve the goal of delivering a multi-target siRNA
drug or a plurality of same-target siRNA drugs to the same cells.